960 / 1266
Investigator-assessed Best Confirmed Response
a
by Tumor Type
Tumor type
High-grade
glioma
n = 8
Low-grade glioma
n = 15
LCH
n = 2
Other solid
tumor
n = 2
Total
N =
27
Best response, n
Complete response
(CR)
3
(2AA, 1 APXA)
2
5
Partial response (PR)
2
(GBM, AGG)
5
(2 PA, PMA, GG, LGG)
7
Stable disease (SD)
7
(3 PA, GG, PXA,
2 LGG)
1
(PTC)
5
Progressive disease
3
(GBM, AG, AA)
1
(PA)
1
(NB)
5
Not evaluable
2
(GG
b,
GG
c
)
5
Response rate, n (%)
CR+PR
5
(63)
5
(33)
2
(100)
0
12
(44)
a
Extracranial solid tumors assessed by RECIST (Response Evaluation Criteria In Solid Tumors); brain tumors assessed by
RANO (Response Assessment in Neuro-Oncology);
b
missing data in eCRF: PI reports SD weeks 8-16;
c
missing data in
eCRF: PI reports PR weeks 16-24.
AA
, anaplastic astrocytoma;
AG
, anaplastic glioma;
AGG
, anaplastic ganglioglioma;
APXA
, anaplastic pleomorphic xanthoastrocytoma ;
GBM
,
gliobastoma multiforme;
GG
, ganglioglioma;
LGG
, low grade glioma;
NB
, neuroblastoma;
PA
, pilocytic astorcytoma;
PMA
, pilomyxoid
astrocytoma;
PTC
, papillary thyroid carcinoma;
PXA
, pleomorphic xanthoastrocytoma.
114